Prime Medical Systems, Inc.(PMSI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Prime Medical Systems, Inc.(PMSI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ken Sims who wrote (145)	8/27/1997 10:35:00 AM
From: l. niedzwiecki	of 210

This is from today's Motley Fool Borefolio recap: "Among Borefolio losers was PRIME MEDICAL SERVICES (Nasdaq: PMSI) (N) (S). Prime shed $1/4 to close at a bid of $10 3/4. Trading volume was slightly above average, which is notable only because activity on most other issues was well below the norm. Some traders may have sold PMSI following news that UROLOGIX (Nasdaq: ULGX) (N) (S) had received FDA approval of its microwave energy device for treating benign prostate hyperplasia BPH). Urologix stock soared on the news. Prime Medical is currently developing mobile routes to offer treatment for BPH with a competing device, the Prostatron manufactured by French company EDAP Technomed. Urologix said in a press release today that they are accelerating their plan to offer their Targis system to urologists nationwide. Although on the surface this news may appear to challenge Prime's strategy, the reality is that both Prime and the urology community have followed the progress of Urologix's product for some time, as well as that of other devices for treating BPH, such as a device manufactured by VIDAMED (Nasdaq: VIDA) (N) (S) that uses radio waves rather than microwaves. I've spoken with Prime and with an analyst who follows the company about the various technologies for treating BPH. Prime has discussed the matter in recent conference calls, as well. As I understand it, the Urologix product has a lower initial cost as compared with the Prostatron, but the consumables used in the treatments cost appreciably more. In any event, Prime is free to use whichever technology makes economic sense. It currently uses more than one kind of lithotripter, and it presumably could use more than one BPH technology. For now, Prime has settled on the Prostatron. At the end of the day, what's likely to matter most is not which device costs somewhat more or somewhat less but rather which company can relate most effectively to the urology community and establish a profitable business venture in partnership with it. In that regard, Prime's record is formidable. The Borefolio team will continue to research this development and will report back as we learn more." Niedz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next